Biotechnology investing for the social good – making money and a difference
There are many foundations and charities which aim to tackle health conditions through funding medical...
There are many foundations and charities which aim to tackle health conditions through funding medical...
CellPryme-A is the latest in a portfolio of platform cell technologies that can not only...
Prescient Therapeutics (ASX: PTX) has presented exciting new data on CellPryme-A at the 7th Annual CAR-TCR...
The cancer drug market could be on the cusp of a timely renaissance as new...
Prescient Therapeutics Ltd (ASX:PTX) has been invited to present two sessions at the upcoming CAR-TCR Summit...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
Prescient will join with the US’s largest cancer centre with the goal of creating best-in-class,...
Prescient Therapeutics (ASX: PTX) takes a crucial step in advancing its next-generation cell therapy platform, OmniCAR. The...
Prescient Therapeutics (PTX) has partnered with the largest cancer centre in the US to create best-in-class,...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.